Literature DB >> 1085283

Preferential generation of killer or helper T-lymphocyte activity directed to the tumour-associated transplantation antigens.

H Fujiwara, T Hamaoka, K Teshima, H Aoki, M Kitagawa.   

Abstract

Induction of killer and helper T-cell activities towards transplantation antigens of two tumour cell lines was analysed in the allogeneic and syngeneic host combinations. The lymphoid cells from C57BL/6 mice immunized with allogeneic viable or mitomycin C-treated X-5563 plasmacytoma cells derived from C3H/He mice revealed both killer and helper T-cell activities against alloantigens, whereas cells from mice immunized with tumour cells killed by a freezing and thawing procedure revealed predominantly helper T-cell activity. On the other hand, when C3H/He mice were immunized with viable syngeneic X-5563 plasmacytoma or MM102 mammary tumour cells, the former generated preferentially killer T-cell activity, whereas the latter induced predominantly helper T-cell activity against tumour-associated transplantation antigens. Thus, immunization with transplantation antigen(s) does not always induce both helper and killer T-cell activities in parallel, but a certain antigenic system induces predominantly one type of T-cell response, thus indicating that two distinct subsets of helper and killer T cells against the transplantation antigen(s) can be raised independently without an absolute requirement of collaboration between these different T-cells subsets.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1085283      PMCID: PMC1445109     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  Immunogenetic analysis of H-2 mutations. III. Genetic mapping and involvement in immune reactions of the H-2ka mutation.

Authors:  J Klein; J Forman; V Hauptfeld; I K Egorov
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

2.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

3.  Transplantion resistance and potent antibody production induced in C3H/He mice against C3H/He mammary tumor by continuous infusion of solubilized antigen.

Authors:  K Takizawa; T Yamamoto; H Mitsui
Journal:  Gan       Date:  1974-12

4.  Selective cytotoxicity in a hapten substituted cell culture model system.

Authors:  G W Philpott; R J Bower; C W Parker
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

5.  Production of anti-H-2 antibodies in thymectomized mice.

Authors:  J Klein; S Livnat; V Hauptfeld; L Jerábek; I Weissman
Journal:  Eur J Immunol       Date:  1974-01       Impact factor: 5.532

6.  Cooperation and cell-mediated cytotoxicity as functions of two subsets of T cells.

Authors:  G Dennert; E S Lennox
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

Review 7.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

Review 8.  T-cell-mediated immune responses induced in vitro: a probe for allograft and tumor immunity.

Authors:  H Wagner; M Röllinghoff; G J Nossal
Journal:  Transplant Rev       Date:  1973

9.  Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  The mechanism of tolerance induction in thymus-derived lymphocytes; I. intracellular inactivation of hapten-reactive helper T lymphocytes by hapten-nonimmunogenic copolymer of D-amino acids.

Authors:  T Hamaoka; U Yamaskita; T Takami; M Kitagawa
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  6 in total

1.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.

Authors:  T Yoshioka; H Fujiwara; Y Takai; M Ogata; J Shimizu; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.

Authors:  H Nakajima; Y Izumi; S Sugihara; Y Satoh; S Isumi; T Gotoh; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.

Authors:  K Sakamoto; H Nakajima; J Shimizu; T Katagiri; C Kiyotaki; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

Authors:  R Maekawa; M Matsumoto; T Kitagawa; M Harada; K Sato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice.

Authors:  N Minato; B R Bloom; C Jones; J Holland; L M Reid
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

6.  Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.

Authors:  T Hamaoka; H Fujiwara; K Teshima; H Aoki; H Yamamoto; M Kitagawa
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.